• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Reassessing Human Adipose Tissue Adipose tissue can more than double in mass and
then return to baseline. This review discusses the functional roles of human white and brown …

The prevalence of obesity has reached pandemic proportions, and now approximately 25%
of adults in Westernized countries have obesity. Recognized as a major health concern …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for
chronic weight management provides a novel effective strategy against obesity. The reliable …

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been widely
recommended for glucose control and cardiovascular risk reduction in patients with type 2 …

Background & Aims Pharmacological management of obesity improves outcomes and
decreases the risk of obesity-related complications. This American Gastroenterological …

Obesity is a chronic, progressive and relapsing disease with a rising global prevalence
associated with increased morbidity and mortality and reduced quality of life. Treatment of …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …